Patients paying more for diabetes medications

Share this article:
Patients paying more for diabetes medications
Patients paying more for diabetes medications

Patients are paying more for type-2 diabetes medications, and a team of Yale University researchers attributes the jump to patient migration from synthetic human and animal insulin to analog insulins.

The study showed the median amount privately insured patients shelled out for diabetes medications rose from $19 to $36 per prescription between 2000 and 2010. Researchers noted analog insulins offer flexible dosing and promise reduced nighttime hypoglycemia, but the difference in severe hypoglycemic events "was not statistically significant."

The cost information may not be a surprise—Express Scripts reported in April that diabetes was among the top-10 most expensive traditional medication categories. The PBM said at the time that use of diabetes medications jumped 14% between 2012 and 2013, and that the amount patients spent on prescription diabetes control beat out the amount of money spent on cholesterol and blood pressure medications.

While both reports show an uptick in patients and use, the latest Centers for Disease Control and Prevention data indicates the actual diabetic population may be much greater and the long-term costs associated with the disease more burdensome. The CDC's latest diabetes patient count is 29.1 million patients, or just over 9% of the US, has diabetes. The asterisk: 8.1 million of these patients do not know they have diabetes.

In addition to the undiagnosed, the CDC also notes that around 37% of US adults qualify as pre-diabetic. This means around 86 million adults could tip into the diabetes category, diagnosed or otherwise.

Controlling the condition itself is imperative because the disease is associated with a slew of conditions, including blindness, kidney disease, heart disease and stroke.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...